KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardlytics (CDLX) Invested Capital (2016 - 2026)

Cardlytics filings provide 11 years of Invested Capital readings, the most recent being -$4.0 million for Q1 2026.

  • Quarterly Invested Capital fell 103.64% to -$4.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$4.0 million through Mar 2026, down 103.64% year-over-year, with the annual reading at $206.1 million for FY2025, 28.59% down from the prior year.
  • Invested Capital hit -$4.0 million in Q1 2026 for Cardlytics, down from $206.1 million in the prior quarter.
  • Across five years, Invested Capital topped out at $711.7 million in Q1 2022 and bottomed at -$4.0 million in Q1 2026.
  • Average Invested Capital over 5 years is $301.4 million, with a median of $266.1 million recorded in 2023.
  • The largest annual shift saw Invested Capital surged 96.71% in 2024 before it crashed 103.64% in 2026.
  • Cardlytics' Invested Capital stood at $211.6 million in 2022, then soared by 85.39% to $392.3 million in 2023, then fell by 26.44% to $288.6 million in 2024, then fell by 28.59% to $206.1 million in 2025, then crashed by 101.94% to -$4.0 million in 2026.
  • Per Business Quant, the three most recent readings for CDLX's Invested Capital are -$4.0 million (Q1 2026), $206.1 million (Q4 2025), and $41.4 million (Q3 2025).